42
total announcements
531592.BO · 15 min delayed
Genpharmasec Ltd
Genpharmasec Ltd has filed a statement with BSE stating that there is no deviation or variation in the use of proceeds from its Rights Issue for the quarter ended 30th September, 2026.
Genpharmasec Ltd
Genpharmasec Ltd has announced the resignation of its Company Secretary and Compliance Officer, Mr. Hardik Makwana, effective November 16, 2026. The company also approved the disinvestment of its wholly-owned subsidiary, Clinigenome India Private Limited, and considered and approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Genpharmasec Ltd
Genpharmasec Ltd has announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company has also approved the disinvestment of its wholly-owned subsidiary, Clinigenome India Private Limited, and the resignation of its Company Secretary and Compliance Officer, Mr. Hardik Makwana.
Genpharmasec Ltd
Genpharmasec Ltd has announced the outcome of its Board Meeting held on November 3, 2026. The Board has approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with a limited review report from the statutory auditor. Additionally, the Board has approved the disinvestment of its entire equity stake in Clinigenome India Private Limited, a wholly-owned subsidiary, and the resignation of Mr. Hardik Makwana as Company Secretary and Compliance Officer.
Genpharmasec Ltd
Genpharmasec Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 03/11/2026 to consider and approve un-audited financial results for the quarter and half year ended September 30, 2026.
Genpharmasec Ltd
Genpharmasec Ltd has informed BSE about the change of name of its subsidiary from GENPHARMASEC MIDDLE EAST DMCC to GENPHARMASEC MIDDLE EAST FZCO, as per the revised naming conventions introduced by the Dubai Multi Commodities Centre.
Genpharmasec Ltd
Genpharmasec Ltd submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026, confirming the dematerialization of securities.
Genpharmasec Ltd
Genpharmasec Ltd has disclosed the voting results and scrutinizer's report of its 34th Annual General Meeting held on 29th September, 2026. The meeting was held through video conferencing, and the resolutions passed include the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and the re-appointment of Mr. Sohan Chaturvedi as a director.
Genpharmasec Ltd
Genpharmasec Ltd has held its 34th Annual General Meeting (AGM) on September 29, 2026, through video conferencing. The meeting approved various resolutions, including the appointment of a director, re-appointment of the whole-time director, and approval for providing loans. The voting results will be submitted in due course.
Genpharmasec Ltd
Genpharmasec Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter and half year ended September 30, 2026.
Genpharmasec Ltd
Genpharmasec Ltd has announced the book closure for its 34th Annual General Meeting (AGM) scheduled to be held on September 29, 2026. The register of members and share transfer books will be closed from September 23 to 29, 2026.
Genpharmasec Ltd
Genpharmasec Ltd has announced the outcome of its Board of Directors meeting held on September 2, 2026, where it considered and approved various items, including the re-appointment of Mr. Sohan Chaturvedi as Whole Time Director and CFO, subject to shareholder approval.
Genpharmasec Ltd
Genpharmasec Ltd has announced the outcome of its Board Meeting held on September 2, 2026, where the Board has approved several items, including the date and time of the 34th Annual General Meeting (AGM), the appointment of a Scrutinizer for the AGM, and the re-appointment of Mr. Sohan Chaturvedi as Whole Time Director.
Genpharmasec Ltd
Genpharmasec Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, indicating that Rajesh Mirchumal Sadhwani and his PACs have acquired 65,00,000 shares of the company, increasing their combined holding to 32.06%.
Genpharmasec Ltd
Genpharmasec Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, indicating that Rajesh Mirchumal Sadhwani has acquired 50,00,000 shares of the company through the open market, increasing his holding to 14.09% from 13.18%.
Genpharmasec Ltd
Genpharmasec Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 to consider and approve various matters, including fixing the day, date, time, and mode of the 34% Annual General Meeting, and approving the Directors Report and Annual Report for the year ended March 31, 2026.
Genpharmasec Ltd
Genpharmasec Ltd has entered into a non-exclusive Super Stockist agreement with Amneal Healthcare Private Limited, committing to a minimum annual sales of INR 75 Crores for each calendar year during the term of the agreement.
Genpharmasec Ltd
Genpharmasec Ltd published unaudited financial results for the quarter ended June 30, 2026, showing a net loss of ₹6.10 lakhs. The company also announced a special window for transfer and dematerialization of physical securities.
Genpharmasec Ltd
Genpharmasec Ltd has submitted a statement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th June, 2026, stating that there is no deviation or variation in the utilization of proceeds from the objects stated in the Letter of Offer. The company has attached a statement of deviation, reviewed by the Audit Committee, to the BSE.
Genpharmasec Ltd
Genpharmasec Ltd has announced unaudited standalone & consolidated financial results for the quarter ended 30th June, 2026, with the Board of Directors considering and approving the same at its meeting held on 11th August, 2026.